TMCnet News
PositiveID's iglucose mobile health device clears FCC testingNov 30, 2011 (Datamonitor via COMTEX) -- PositiveID Corporation, a developer of medical technologies for diabetes management and clinical diagnostics, has announced that the company's iglucose mobile health device has completed all Federal Communications Commission, or FCC, required testing. The iglucose System meets the regulatory requirements of the FCC to be sold in the US PositiveID recently received clearance from the FDA to market the iglucose System in the US. iglucose uses mobile technology to empower individuals with diabetes to be more engaged in the self-management of their condition by eliminating the need to keep manual logbooks. iglucose wirelessly and seamlessly communicates blood glucose readings from data-capable glucometers to the iglucose diabetes management portal, where, with the user's consent, glucose readings can be shared automatically with family members, caregivers and healthcare professionals via text message, email or fax. The iglucose diabetes management portal creates graphs, charts and reports that can help people with diabetes and their healthcare professionals track blood glucose levels and improve diabetes management plans. iglucose does not require the use of a cell phone or a wireless plan. PositiveID intends to bring iglucose to market in the first quarter of 2012 through initial roll-outs with healthcare insurers and home-healthcare providers. The goal of these pilot programs is to receive insurance reimbursement for iglucose. The Company believes the initial pilot programs, after an evaluation period, will lead to widespread adoption among the patient base. "Successfully passing all FCC required testing of iglucose so soon after receiving FDA clearance, we believe, is a testament to our excellent engineering team and device design, which enabled us to pass all certification testing with no redesigns required. All wireless communication devices must pass FCC certification prior to commercial launch, and these mandatory regulatory clearances now position us to bring iglucose, a first-of-its-kind product, to market to simplify the lives of individuals with diabetes," stated William J. Caragol, CEO of PositiveID. http://www.datamonitor.com Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon |